PAYS:NASDAQPaysign, Inc. Analysis
Data as of 2026-04-23 - not real-time
$6.07
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Paysign’s price sits above its DCF‑derived fair value, with the 20‑day SMA comfortably above the 50‑day SMA, suggesting a neutral technical stance but modest upside pressure. The RSI hovers in the low‑60s, indicating the stock is nearing overbought territory, while the MACD histogram has turned slightly negative, a bearish signal that tempers short‑term enthusiasm. Revenue is expanding at a rapid 45% annual rate and gross margins sit near 60%, providing a solid foundation for future earnings growth. However, the forward P/E of roughly 16 is well below the trailing P/E of 47, highlighting a potential earnings acceleration that the market has not fully priced in. Volatility is extremely high at over 110% on a 30‑day basis and beta exceeds 1.5, underscoring heightened market risk. Recent news points to growing fintech momentum and a bullish sentiment shift, yet the stock remains modestly down year‑to‑date, reflecting a mixed narrative.
The balance sheet is relatively clean with cash outpacing debt, and free cash flow remains positive, supporting operational flexibility. Despite the lack of dividend, the company’s ROE near 19% and improving operating cash flow suggest efficient capital use. The support level around $4.94 provides a cushion, but the nearest resistance near $6.55 limits near‑term upside. Overall, the blend of strong growth fundamentals, elevated valuation, and pronounced price volatility calls for a measured approach: cautious in the short run, more optimistic over medium to long horizons.
The balance sheet is relatively clean with cash outpacing debt, and free cash flow remains positive, supporting operational flexibility. Despite the lack of dividend, the company’s ROE near 19% and improving operating cash flow suggest efficient capital use. The support level around $4.94 provides a cushion, but the nearest resistance near $6.55 limits near‑term upside. Overall, the blend of strong growth fundamentals, elevated valuation, and pronounced price volatility calls for a measured approach: cautious in the short run, more optimistic over medium to long horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- MACD histogram negative
- RSI approaching overbought
- Decreasing volume trend
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth and expanding margins
- Forward P/E compression
- Positive earnings momentum from recent fintech narrative
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable cash generation and low debt
- High ROE and improving free cash flow
- Strategic positioning in growing prepaid and patient‑affordability markets
Key Metrics & Analysis
Financial Health
Revenue Growth45.80%
Profit Margin9.21%
P/E Ratio46.7
ROE19.13%
ROA1.95%
Debt/Equity12.43
P/B Ratio6.9
Op. Cash Flow$52.5M
Free Cash Flow$8.0M
Industry P/E36.9
Technical Analysis
TrendNeutral
RSI63.5
Support$4.94
Resistance$6.55
MA 20$5.87
MA 50$4.47
MA 200$5.28
MACDBearish
VolumeDecreasing
Fear & Greed Index86.71
Valuation
Fair Value$5.62
Target Price$9.80
Upside/Downside61.45%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.59
Volatility111.76%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.